Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Patients who are borderline diabetic, have significant excess fat or carry increased cardiovascular risk may need standard-dose GLP-1 therapy
usually most pronounced during dose escalation Diarrhea : Affects 12-17% of patients, typically mild to moderate in severity Vomiting : Reported in 6-10% of patients, more common at higher doses Constipation : Occurs in 6-11% of patients Abdominal pain and dyspepsia : Generally transient Decreased appetite : An expected pharmacological effect contributing to weight loss Other documented adverse effects include injection site reactions, hypoglycemia (when used with insulin or sulfonylureas), and less commonly, fatigue
Concerned people must collaborate with healthcare providers for complete information regarding documentation and the exact type of anemia being treated
Thank you for the fast, uncomplicated delivery
SantosMCNunesCCappelleJGonalvesFJRodriguesASaraivaJAet al
H.HuangZ.WuJ.DingC
